ut microbiota-derived metabolites are novel targets for improving insulin resistanc

Autor(es)

Bastos, Rosana M. C. ^[1] ; Rangel, Erika B. ^{[2, 1]}

Afiliação do(s) autor(es)

^[1] Hosp Israelita Albert Einstein, Albert Einstein 627, Bldg A, 2SS, BR-05652001 Sao Paulo, SP - Brazil

^[2] Univ Fed Sao Paulo, Div Nephrol, BR-04023900 Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: WORLD JOURNAL OF DIABETES; v. 13, n. 1, p. 65-69, JAN 15 2022.
• Citações Web of Science: 0

Resumo

The gut microbiota plays a key role in metabolic diseases. Gut-microbiota-derived metabolites are found in different dietary sources, including: Carbohydrate (acetate, propionate, butyrate, also known as short-chain fatty acids, as well as succinate); protein (hydrogen sulfide, indole, and phenylacetic acid); and lipids (resveratrol-, ferulic acid-, linoleic acid-, catechin- and berry-derived metabolites). Insulin resistance, which is a global pandemic metabolic disease that progresses to type 2 diabetes mellitus, can be directly targeted by these metabolites. Gut-microbiota-derived metabolites have broad effects locally and in distinct organs, in particular skeletal muscle, adipose tissue, and liver. These metabolites can modulate glucose metabolism, including the increase in glucose uptake and lipid oxidation in skeletal muscle, and decrease in lipogenesis and gluconeogenesis associated with lipid oxidation in the liver through activation of phosphatidylinositol 3-kinase - serine/threonine-protein kinase B and AMP-activated protein kinase. In adipose tissue, gut-microbiota-derived metabolites stimulate adipogenesis and thermogenesis, inhibit lipolysis, and attenuate inflammation. Importantly, an increase in energy expenditure and fat oxidation occurs in the whole body. Therefore, the therapeutic potential of current pharmacological and non-pharmacological approaches used to treat diabetes mellitus can be tested to target specific metabolites derived from intestinal bacteria, which may ultimately ameliorate the hyperglycemic burden. (AU)

• Processo FAPESP: 17/23195-2 - Terapia com células-tronco mesenquimais como abordagem terapêutica para reduzir a progressão das lesões renais agudas e crônicas e para modular in vivo as células-tronco c-Kit específicas do tecido renal
• Beneficiário: Érika Bevilaqua Rangel
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 13/19560-6 - As células c-kit positivas são células-tronco específicas do rim e apresentam capacidade regenerativa
• Beneficiário: Érika Bevilaqua Rangel
• Modalidade de apoio: Auxílio à Pesquisa - Regular